Small by design, built for the demands of modern genetic medicine across gene therapy, cell therapy, and vaccines 

VectorBuilder, a global leader in gene delivery technologies and CDMO services,  announced that its MiniVec™ plasmid system has been granted a European patent, marking a significant milestone for the company’s proprietary plasmid DNA technology and reinforcing its position at the forefront of gene delivery innovation. 

MiniVec™ was developed to remove constraints that have historically limited plasmid safety, scalability, and regulatory acceptance. By minimizing bacterial-derived sequences on its plasmid backbone, MiniVec™ eliminates the need for antibiotic selection and reliance on chemical additives for plasmid maintenance and fermentation. The European patent covers the underlying plasmid system design and associated production approaches of MiniVec™, providing formal recognition of the novelty of this design architecture and its applicability to modern genetic medicine development. It is expected to support ongoing patent considerations in other major markets, such as the United States, Australia, Japan, Korea, and China.  

“This patent reflects a fundamental shift in how plasmid systems can be designed for clinical use,” said Dr. Bruce Lahn, Chief Scientist of VectorBuilder. “Many of the challenges developers encounter later, whether in manufacturing, safety, or regulatory review, can be traced back to early design decisions. MiniVec™ was developed to remove these constraints at the source, improving how plasmids perform across the entire development pipeline.” 

The development of MiniVec™ reflects how expectations for plasmid systems are evolving, with increasing emphasis on manufacturability, consistency, and patient safety across both clinical development and large-scale production. 

Manufacturing efficiency at scale 

MiniVec™ is optimized to simplify plasmid production while improving output. Its miniaturized backbone supports antibiotic-free and additive-free production, reducing process complexity in GMP environments and showing consistent yield gains across vector types. Notably, these gains increase at manufacturing scale, directly lowering the cost of goods for GMP-grade plasmid production. 

Performance across therapeutic applications 

MiniVec™ contributes to measurable performance improvements across multiple applications. Compared to traditional plasmids, MiniVecTM achieved higher viral titers, higher CRISPR-mediated genome integration activity, consistent gains across transposon systems, and higher antibody titers in DNA vaccine models. In cell therapy workflows, it showed significant improvement in T-cell electroporation efficiency compared to traditional plasmids, with direct implications for CAR-T manufacturing throughput and dose consistency. 

Safety profile and regulatory alignment 

MiniVec™ has been systematically evaluated in vivo, including acute and repeated-dose studies assessing hematological, biochemical, and organ-level parameters, with no adverse effects observed. This profile aligns with FDA and EMA expectations to remove antibiotic resistance genes and unnecessary genetic elements, supporting the development of clinically relevant plasmid systems. 

The European patent milestone highlights the potential of MiniVec™ across multiple areas of genetic medicine, including cell and gene therapy, DNA vaccine development, and emerging in vivo therapeutic approaches. In addition, its simplified and antibiotic-free design is advantageous in fields such as food-alternative biotechnology, where regulatory requirements for genetic materials are particularly stringent. As demand for scalable, regulatory-ready plasmid systems grows, MiniVec™ is positioned to play an increasingly important role in supporting the next generation of genetic medicines and biologics.